relapsed

Brentuximab, a chimeric antibody targeting CD30, is a naked antibody to Brentuximab vedotin. It possesses antitumor activity and may be used to study relapsed or refractory Hodgkin's lymphoma.

Glofitamab (RO7082859) is a novel bivalent antibody directed against CD20-binding T cells.Glofitamab promotes T cell proliferation and activation and tumor cell killing by binding to CD20 on malignant cells.Glofitamab can be used for the palliation of relapsed or refractory B-cell lymphomas.

Mosunetuzumab (BCT-4465A) is a humanized antibody based on immunoglobulin G1 that targets CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used to study relapsed or refractory (R R) B-cell non-Hodgkin lymphoma (B-NHL) and refractory follicular lymphoma.

Teclistamab (JNJ-64007957) is a human bispecific monoclonal antibody targeting the CD3 receptor expressed on the surface of t-cells and the b-cell maturation antigen (BCMA) expressed on the surface of malignant multiple myeloma b-lineage cells for the treatment of relapsed and refractory multiple myeloma.

Bersanlimab (BI-505) is a fully human monoclonal antibody targeting Intercellular Adhesion Molecule-1 (ICAM-1), demonstrating anticancer properties and applicable for studying relapsed refractory multiple myeloma.

Rosmantuzumab (OMP-131R10) is a humanized monoclonal antibody against R-spondin 3 (RSPO3). Rosmantuzumab has potential antitumor activity and can be used to study advanced relapsed refractory solid tumors.

Epcoritamab (GEN3013) is a novel subcutaneous CD3xCD20 bispecific T-cell binding antibody that activates T-cells and directs them to kill malignant CD20(+) B-cells for the study of relapsed or refractory large B-cell lymphoma.

Linvoseltamab, a bispecific antibody, targets both BCMA (TNFRSF17) and CD3 epsilon, demonstrating a favorable safety profile and promising efficacy in relapsed refractory multiple myeloma (RRMM) [1][2].

Visugromab, a GDF-15 neutralizing IgG4 monoclonal antibody (mAb), demonstrates potent efficacy in treating PD-1 PD-L1 relapsed refractory metastatic solid tumors [1].

Azintuxizumab, an IgG4 bispecific antibody, specifically targets the B-cell maturation antigen (BCMA) and shows promise for the investigation of relapsed refractory multiple myeloma (RRMM) [1].

Emirodatamab (AMG-427) is an anti-FLT3 CD3 bispecific T-cell engager with an extended half-life. It can induce high cytotoxicity in primary AML progenitor cells and enhance FLT-3 expression. Combining Emirodatamab with anti-PD-1 antibodies increases T-cell dependent cytotoxicity (TDCC). This compound is under investigation for use in relapsed or refractory AML.

Elranatamab (PF-06863135) is a humanized bispecific antibody that targets BCMA (B-cell maturation antigen) on myeloma cells and CD3 on T cells. By targeting these molecules, Elranatamab activates T cells and directs them to induce a cytotoxic T cell response against myeloma cells. This compound is used in research for relapsed or refractory multiple myeloma.